Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. -67. (Canceled)

68. (Currently Amended) A method for treating a patient, comprising:

delivering an angioplasty balloon to a site along a lumen in the patient;

inflating the balloon to contact a wall of the lumen at the site; and

locally delivering to the lumen wall at the site a volume of ~~at least one bioactive agent selected from the group consisting of a~~ des-methyl tocopherol~~, a phytyl substituted chromanol, and a palm oil agent~~, or a precursor, analog, or derivative thereof.

69. (Canceled).

70. (Currently amended) The method of claim 68, wherein the ~~first bioactive agent comprises~~ des-methyl tocopherol is a gamma-tocopherol agent.

71. (Currently Amended) The method of claim 68, wherein said volume comprises a precursor of the ~~first bioactive agent~~ des-methyl tocopherol that comprises a DNA plasmid encoding the production of ~~said first bioactive agent~~ the des-methyl tocopherol.

72. (Currently Amended) The method of claim 68, wherein said volume comprises a precursor of the ~~first bioactive agent~~ des-methyl tocopherol that comprises a viral or non-viral gene vector encoding the production of ~~said first bioactive agent~~ the des-methyl tocopherol.

73. (Previously Presented) The method of claim 68, further comprising:
delivering an endolumenal stent to the site;
deploying the stent to contact the wall at the site; and
delivering the volume into the wall at the site from the deployed stent.

74. (Previously Presented) The method of claim 73, further comprising:
coating or adsorbing the stent with a delivery carrier containing the volume; and
delivering the volume to the wall at the site via release from the delivery carrier.

75. (Previously Presented) The method of claim 68, further comprising:
coupling said volume to the angioplasty balloon; and
delivering said volume to the wall at the site by releasing the volume from the angioplasty balloon.

76. (Currently Amended) The method of claim 68, further comprising:
administering a therapeutic dose of ~~said first bioactive agent~~ the des-methyl tocopherol in said volume in a manner providing a higher bioactivity of the of ~~first bioactive agent~~ des-methyl tocopherol at said site than elsewhere in the body.

77. (Currently Amended) The method of claim 68, further comprising:
in combination with said volume of ~~first bioactive agent~~ des-methyl tocopherol, delivering into the wall at the site a therapeutic dose of a second bioactive agent that is different from ~~said first bioactive agent~~ the des-methyl tocopherol.

78. (Previously Presented) The method of claim 77, wherein said second bioactive agent comprises an anti-restenosis agent delivered in a manner that provides a higher bioactivity at said site than elsewhere in the body.

79. (Previously Presented) The method of claim 78, wherein said dose of antirestenosis agent is delivered in a manner sufficient to inhibit restenosis at said site following balloon angioplasty or stent implantation.

80. (Previously Presented) The method of claim 78, wherein said antirestenosis agent comprises at least one agent selected from the group consisting of sirolimus, tacrolimus, everolimus, ABT-578, paclitaxel, dexamethasone, 17-betaestradiol, steroid, des-aspartate angiotensin I (DAA-1), angiotensin converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor blocker, tachykinin, sialokinin, apocynin, pleiotrophin, exochelin, an iron chelator, VEGF, heparin, coumadin, c1opidogrel, IIb/IIIa inhibitor, nitric oxide, a nitric oxide donor, an eNOS antagonist, a nitric oxide synthesis promoter, and a statin, or a precursor, analog, or derivative thereof, or a combination or blend thereof.

81. (Previously Presented) The method of claim 77, further comprising:

locally delivering the first bioactive agent and second bioactive agent into the wall at the site.

82. (Currently Amended) The method of claim 80, further comprising:

eluting at least one of ~~said first bioactive agent~~ the des-methyl tocopherol and said second bioactive agent from the angioplasty balloon or an implanted stent into the wall at the site.

83. (Currently Amended) The method of claim 80, further comprising:

systemically delivering the other of ~~said first and~~ the des-methyl tocopherol and the second bioactive ~~agents~~ agent.

84. (Currently Amended) The method of claim 77, further comprising:

eluting both the ~~first~~ des-methyl tocopherol and the second bioactive ~~agents~~ agent from the angioplasty balloon or an implanted stent.

85. (Currently Amended) The method of claim 77, further comprising:

coating an implantable endolumenal stent with a porous non-polymeric carrier matrix;

holding the volume of ~~first bioactive agent~~ des-methyl tocopherol principally within the porous metal carrier matrix;

delivering and deploying the stent to contact the wall at the site; and

eluting the volume from the matrix into the wall at the site from the deployed stent.

86. (Currently Amended) A system for treating a patient, comprising:

an angioplasty balloon that is deliverable to a site along a lumen in a patient and is inflatable to contact a wall of the lumen at the site;

a volume of a pharmaceutically acceptable preparation of ~~a first bioactive agent selected from the group consisting of~~ des-methyl tocopherol~~, a phytyl substituted chromanol, and a palm oil agent~~, or a precursor, analog, or derivative thereof; and

a local drug delivery system coupled to the volume and configured to deliver the volume to the lumen wall at the site.

87. (Canceled).

88. (Previously Presented) The system of claim 86, wherein:

said local drug delivery system comprises a carrier coupling the volume to at least one of the angioplasty balloon and an implantable endolumenal stent;

said volume is held and deliverable to the wall at the site via release from the carrier.